Angela N Bartley1, Mary Kay Washington2, Christina B Ventura3, Nofisat Ismaila4, Carol Colasacco3, Al B Benson5, Alfredo Carrato6, Margaret L Gulley7, Dhanpat Jain8, Sanjay Kakar9, Helen J Mackay10, Catherine Streutker11, Laura Tang12, Megan Troxell13, Jaffer A Ajani14. 1. From the Department of Pathology, St Joseph Mercy Hospital, Ann Arbor, MI angelbart16@gmail.com. 2. Department of Pathology, Vanderbilt University Medical Center, Nashville, TN. 3. Surveys and Governance, College of American Pathologists, Northfield, IL. 4. Quality and Guidelines Department, American Society of Clinical Oncology, Alexandria, VA. 5. Division of Hematology/Oncology, Northwestern University, Chicago, IL. 6. Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain. 7. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill. 8. Department of Pathology, Yale University School of Medicine, New Haven, CT. 9. Department of Pathology and Laboratory Medicine, UCSF, San Francisco, CA. 10. Division of Medical Oncology and Hematology, University of Toronto/Sunnybrook Odette Cancer Centre, Toronto, Canada. 11. Department of Laboratory Medicine, St Michael's Hospital, Toronto, Canada. 12. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 13. Department of Pathology, Stanford University Medical Center, Stanford, CA. 14. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
Abstract
CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants. RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.
CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants. RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.
Authors: J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Harry H Yoon; Qian Shi; William R Sukov; Mark A Lewis; Christopher A Sattler; Anne E Wiktor; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: Charlotte I Stroes; Sandor Schokker; Aafke Creemers; Remco J Molenaar; Maarten C C M Hulshof; Stephanie O van der Woude; Roel J Bennink; Ron A A Mathôt; Kausilia K Krishnadath; Cornelis J A Punt; Rob H A Verhoeven; Martijn G H van Oijen; Geert-Jan Creemers; Grard A P Nieuwenhuijzen; Maurice J C van der Sangen; Laurens V Beerepoot; Joos Heisterkamp; Maartje Los; Marije Slingerland; Annemieke Cats; Geke A P Hospers; Maarten F Bijlsma; Mark I van Berge Henegouwen; Sybren L Meijer; Hanneke W M van Laarhoven Journal: J Clin Oncol Date: 2019-12-06 Impact factor: 44.544
Authors: Maristela L Onozato; Clarence Yapp; Douglas Richardson; Tilak Sundaresan; Varun Chahal; Jesse Lee; James P Sullivan; Marisa W Madden; Hyo S Shim; Matthew Liebers; Quan Ho; Shyamala Maheswaran; Daniel A Haber; Zongli Zheng; Brian Clancy; Hunter L Elliott; Jochen K Lennerz; A John Iafrate Journal: J Mol Diagn Date: 2019-03-09 Impact factor: 5.568
Authors: Willemieke P M Dijksterhuis; Rob H A Verhoeven; Sybren L Meijer; Marije Slingerland; Nadia Haj Mohammad; Judith de Vos-Geelen; Laurens V Beerepoot; Theo van Voorthuizen; Geert-Jan Creemers; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: Gastric Cancer Date: 2020-01-11 Impact factor: 7.370
Authors: Aafke Creemers; Eva A Ebbing; Gerrit K J Hooijer; Lisanne Stap; Rajni A Jibodh-Mulder; Susanne S Gisbertz; Mark I van Berge Henegouwen; Maurits L van Montfoort; Maarten C C M Hulshof; Kausilia K Krishnadath; Martijn G H van Oijen; Maarten F Bijlsma; Sybren L Meijer; Hanneke W M van Laarhoven Journal: Oncotarget Date: 2018-06-01